Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06308653 · ClinicalTrials.gov registry record · Phase 3
Psilocybin for Major Depressive Disorder (MDD)
A Phase 3 study of Depressive Disorder, Major, sponsored by Usona Institute.
- Active
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT06308653 is a Phase 3 study of Depressive Disorder, Major that is active but no longer recruiting, run by Usona Institute. The registered enrollment target is 240 participants, roughly in line with the 238-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target. The trial reports 20 study locations across 12 states.
The verdict
NCT06308653, a Phase 3 study of Depressive Disorder, Major, is active but no longer recruiting, sponsored by Usona Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between groups in change in depressive symptoms from Baseline to Day 43 post-dose, and to characterize the durability of initial treatment effect and subsequent response to optional Psilocybin 25 mg re-administration(s) during the 1-year Follow-up Period.
Conditions Studied
Interventions
- DRUG Psilocybin 25 mg
- DRUG Inactive Placebo
- DRUG Psilocybin 5 mg
- BEHAVIORAL Psychosocial Support
Study Locations (20)
California
- Kadima Neuropsychiatry Institute - La Jolla
- West LA VA Medical Center - Mental Health Department - Los Angeles
- Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners - Santa Monica
- Psychedelic Science Institute - Santa Monica
Florida
- Clinical Neuroscience Solutions Inc. - Jacksonville
- Innovative Clinical Research, Inc. - Lauderhill
- Clinical Neuroscience Solutions, Inc. - Orlando
Arkansas
- Preferred Research Partners-NWA, LLC - Fayetteville
- Preferred Research Partners, Inc. - Little Rock
Georgia
- Emory University - Atlanta
- CenExel iResearch, LLC - Decatur
Maryland
- Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness Research - Baltimore
- Sunstone Medical PC - Rockville
Alabama
- University of Alabama Clinical Research Unit - Birmingham
Colorado
- Mountain View Clinical Research - Denver
Connecticut
- Connecticut Mental Health Center, Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-03-13 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06308653
The ClinicalTrials.gov registry entry for NCT06308653 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 238-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target. The listed sponsor is Usona Institute, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 4 interventions - of which Psilocybin 25 mg is the first listed.
NCT06308653 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06308653 about?
NCT06308653 is a clinical study titled "Psilocybin for Major Depressive Disorder (MDD)". Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin ...
What is the current status of trial NCT06308653?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2024-03-13. Estimated completion is 2026-12-30.
What conditions does trial NCT06308653 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT06308653?
The interventions under investigation include: Psilocybin 25 mg (DRUG), Inactive Placebo (DRUG), Psilocybin 5 mg (DRUG), Psychosocial Support (BEHAVIORAL).
Who is sponsoring clinical trial NCT06308653?
This trial is sponsored by Usona Institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06308653 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 3
-
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
RECRUITING · Phase 3
-
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
ACTIVE NOT RECRUITING · Phase 3
-
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
COMPLETED · Phase 3
-
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.